Navigation Links
Miscarriage and infertility treatment increase pre-eclampsia risk
Date:12/18/2008

Repeated miscarriages and hormone treatment for infertility give an increased risk of pre-eclampsia among pregnant women. This comes from a new study from the Norwegian Institute of Public Health. More than 20 000 first-time mothers from the Norwegian Mother and Child Cohort Study (MoBa) were included in the study.

Normal risk

  • First-time mothers who had not miscarried or had problems getting pregnant had a 5.2 % risk of pre-eclampsia.

Risk after miscarriage

  • Women who had three or more miscarriages had a 50 % increased risk of pre-eclampsia compared with women who had not miscarried.
  • Women who had one or two miscarriages are not thought to be at higher risk.
  • Among women who had both miscarriages and treatment for infertility, the risk for pre-eclampsia was 13 %.

Risk after infertility treatment

  • The study also shows that women who had infertility treatment had a 25 % higher risk of pre-eclampsia.
  • Women who became pregnant after hormone treatment to stimulate ovulation had a doubled risk of pre-eclampsia compared to women without treatment.
  • Assisted conception treatment was not linked to an increased risk, even though hormone stimulation is part of the procedure.
  • Different causes of infertility (polycystic ovary syndrome, blocked Fallopian tubes etc.) can probably explain the difference in risk for pre-eclampsia. It is likely that factors in mothers that cause infertility may also give an increased risk of pre-eclampsia.
  • It is less likely that the treatment itself explains the increased risk, even if this cannot be excluded.

The study has been recently published in the British Journal of Obstetrics and Gynaecology, BJOG.

Placenta important for normal development

The causes of pre-eclampsia are unknown, but involve the placenta. The placenta is important for normal development of the pregnancy. Failure in the development and function of the placenta seems to be an important mechanism in the development of pre-eclampsia but no-one knows why. The results from this study show that the protective effect seen after earlier normal pregnancies (births or terminations) is not present among women with repeated miscarriages. The study indicates that common causal factors linked to the placenta's development and function may be present in infertility, repeated miscarriages and pre-eclampsia.

Facts about pre-eclampsia

  • Affects 3-5 % of all pregnant women.
  • Greatest risk among first-time mothers.
  • Appears in second half of pregnancy
  • Recognised by high blood pressure and protein in mother's urine.
  • In mild cases the mother can be unaffected by the condition, but in serious cases, pre-eclampsia can be life-threatening for mother and baby, with organ failure and danger of seizures among mothers.
  • The child risks poor growth and development due to insufficient placenta function.
  • The only treatment is delivery of baby and placenta.
  • Pre-eclampsia is therefore an important cause of premature birth.
  • Among women who have given birth earlier, the risk is approximately halved. The same applies to women who have had earlier terminations. It is unknown why earlier normal pregnancies protect against pre-eclampsia in later pregnancies.


'/>"/>

Contact: Media Contact
julie.johansen@fhi.no
Norwegian Institute of Public Health
Source:Eurekalert

Related biology news :

1. Statins may prevent miscarriages
2. Proteins in sperm unlock understanding of male infertility says new study
3. Diabetes linked to male infertility; excess sugars in the body have direct effect on sperm quality
4. USC researchers explore genetic causes for male infertility
5. UC Davis team refines cancer treatments to reduce potential nerve damage
6. In just 5 years, gene discovery to clinical trial of potential treatment
7. Leeds research points to new therapy for hepatitis C treatment
8. Epilepsy drug shows potential for Alzheimers treatment
9. First trial in patients with a potential treatment of the incurable ALS muscle disease
10. Scientists developing food allergy treatment
11. Inherited genetic cause, possible treatment found for complex lung disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions ... Identity management products and solutions and a cutting-edge ... today that it is offering seamless, integrated solutions ... security entrance products. The solutions provide IdentyTech,s customers ... secure their facilities from crime and theft. ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots ... scientists from around the world, was today awarded the "Best Science & Technology ... entirely on merit and decided upon by a dedicated team of researchers and ...
(Date:1/19/2017)... Md. , Jan. 18, 2017  Northwest Biotherapeutics, ... developing DCVax® personalized immune therapies for operable and inoperable ... Bosch , Chief Technical Officer of NW Bio, will ... January 19, 2017, at the Hyatt Regency Hotel in ... Bosch will chair the session entitled "New Therapeutic Approaches ...
(Date:1/18/2017)... According to a new market research report "In situ ... & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast ... Million by 2021 from USD 557.1 Million in 2016, growing at a CAGR ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive ... 2017 in its continued commitment to the advancement of the clinical trials segment. ... issues related to clinical trial planning and management. , As executive talent ...
Breaking Biology Technology: